Bexarotene and narrowband ultraviolet B phototherapy combination treatment for mycosis fungoides
Authors:
- 1 November 2007
- journal article
- case report
- Published by Wiley in Photodermatology, Photoimmunology & Photomedicine
- Vol. 23 (6) , 255-257
Abstract
Combination therapy for mycosis fungoides (MF) has the potential to be synergistic, improve therapeutic efficacy and reduce toxicities. We present a patient with MF who improved on combination therapy with bexarotene and narrowband ultraviolet B (NB‐UVB) therapy. The patient is an 81‐year‐old Caucasian male who initially presented with stage IB MF. After temporary improvement with NB‐UVB phototherapy, he progressed to develop plaques and tumors. Psoralen and ultraviolet A therapy was contraindicated because of ophthalmologic disease. Addition of bexarotene 300 mg daily led to rapid clinical improvement in combination with NB‐UVB. Interruption of NB‐UVB during a prolonged hospitalization led to a clinical flare of lesions, despite continued treatment with bexarotene. Reinitiating NB‐UVB was associated with clinical improvement. This report demonstrates that combination treatment with oral bexarotene and NB‐UVB therapy may represent a safe alternative for the treatment of plaque‐stage MF.Keywords
This publication has 7 references indexed in Scilit:
- Immunopathogenesis and therapy of cutaneous T cell lymphomaJournal of Clinical Investigation, 2005
- Immunopathogenesis and therapy of cutaneous T cell lymphomaJournal of Clinical Investigation, 2005
- Biological Effects of Bexarotene in Cutaneous T-Cell LymphomaArchives of Dermatology, 2005
- Narrowband UVB and psoralen-UVA in the treatment of early-stage mycosis fungoides: A retrospective studyJournal of the American Academy of Dermatology, 2003
- Optimizing bexarotene therapy for cutaneous T-cell lymphomaJournal of the American Academy of Dermatology, 2002
- Oral Bexarotene in the Treatment of Cutaneous T-Cell LymphomaAnnals of Pharmacotherapy, 2001
- Oral Bexarotene in the Treatment of Cutaneous T-Cell LymphomaAnnals of Pharmacotherapy, 2001